TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Cardiologists agree: Early TAVR or SAVR for asymptomatic severe AS limits strokes, hospitalizations
Two separate groups have published new research comparing early AVR with clinical surveillance for the treatment of asymptomatic severe aortic stenosis. Overall, the two groups found, early treatment was associated with multiple benefits—and no added risk of harm.
Cardiologists are first in world to use new TAVR catheter from Boston Scientific
The new Self-Centering Guide Catheter was designed to help care teams with the retrograde crossing of the aortic valve during TAVR. Researchers evaluated the safety and effectiveness of the catheter, sharing their experience in JACC: Cardiovascular Interventions.
TAVR vs. SAVR: Real-world data highlight advantages of both techniques
The biggest differences, researchers noted, were found in the long-term outcomes of low- and intermediate-risk patients.
Cardiologists treat first commercial patients with FDA-cleared valve-in-valve TAVR device
Pi-Cardia, an Israeli medtech company, describes ShortCut as the “world’s first dedicated leaflet modification device."
Popular TAVR valves linked to comparable long-term outcomes
Second-generation TAVR valves from Medtronic, Edwards Lifesciences and Boston Scientific are all associated with similar seven-year outcomes, according to a new retrospective study out of Italy.

Cardiologists agree: Early TAVR or SAVR for asymptomatic severe AS limits strokes, hospitalizations

Two separate groups have published new research comparing early AVR with clinical surveillance for the treatment of asymptomatic severe aortic stenosis. Overall, the two groups found, early treatment was associated with multiple benefits—and no added risk of harm.

self-centering guide catheter (SCGC) for TAVR from Boston Scientific

Cardiologists are first in world to use new TAVR catheter from Boston Scientific

The new Self-Centering Guide Catheter was designed to help care teams with the retrograde crossing of the aortic valve during TAVR. Researchers evaluated the safety and effectiveness of the catheter, sharing their experience in JACC: Cardiovascular Interventions.

heart data research doctor cardiologist AI

TAVR vs. SAVR: Real-world data highlight advantages of both techniques

The biggest differences, researchers noted, were found in the long-term outcomes of low- and intermediate-risk patients.

Cardiologists treat first commercial patients with FDA-cleared valve-in-valve TAVR device

Pi-Cardia, an Israeli medtech company, describes ShortCut as the “world’s first dedicated leaflet modification device."

The Medtronic CoreValve Evolut and the Edwards Lifesciences Sapien 3 TAVR valves.

Second-generation TAVR valves from Medtronic, Edwards Lifesciences and Boston Scientific are all associated with similar seven-year outcomes, according to a new retrospective study out of Italy.

Newsweek ranked the 50 best heart hospitals in the world

Know your options: What cardiologists recommend when alternative access is required for TAVR

Transfemoral TAVR is not always a viable option. In those instances, the two most effective alternatives are transcarotid access and transcaval access, according to a new SCAI expert consensus statement.

Aakriti Gupta, MD, Cedars-Sinai, explains use of cerebral embolic protection devices in TAVR

An updated look at the use of cerebral embolic protection devices during TAVR

Cardiologist Aakriti Gupta, MD, MSc, spoke to Cardiovascular Business about the latest data and trends associated with using cerebral embolic protection devices during TAVR to lower the risk of stroke.

Veterans with heart disease often receive better care through VA than they would elsewhere

Military veterans face an increased risk of cardiovascular disease, making it especially important to ensure they receive high-quality care.

TAVR

Cardiologists agree: Early TAVR or SAVR for asymptomatic severe AS limits strokes, hospitalizations

Cardiologists are first in world to use new TAVR catheter from Boston Scientific

TAVR vs. SAVR: Real-world data highlight advantages of both techniques

Cardiologists treat first commercial patients with FDA-cleared valve-in-valve TAVR device

Popular TAVR valves linked to comparable long-term outcomes